Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

125 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant Hypofractionated Whole Breast Irradiation (WBI) vs. Accelerated Partial Breast Irradiation (APBI) in Postmenopausal Women with Early Stage Breast Cancer: 5Years Update of the HYPAB Trial.
Lo Faro L, Fogliata A, Franceschini D, Spoto R, Dominici L, Bertolini A, Stefanini S, Vernier V, Ilieva MB, Scorsetti M. Lo Faro L, et al. Among authors: stefanini s. Clin Breast Cancer. 2024 Apr;24(3):253-260. doi: 10.1016/j.clbc.2023.12.012. Epub 2024 Jan 5. Clin Breast Cancer. 2024. PMID: 38220538 Clinical Trial.
Phase II trial of stereotactic body radiation therapy on adrenal gland metastases: evaluation of efficacy and impact on hormonal production.
Franzese C, Stefanini S, Massaro M, Comito T, Navarria P, Clerici E, Teriaca A, Franceschini D, Reggiori G, Tomatis S, Lania A, Scorsetti M. Franzese C, et al. Among authors: stefanini s. J Cancer Res Clin Oncol. 2021 Dec;147(12):3619-3625. doi: 10.1007/s00432-021-03807-z. Epub 2021 Sep 18. J Cancer Res Clin Oncol. 2021. PMID: 34537907 Clinical Trial.
Stereotactic Body Radiation Therapy for Lung and Liver Oligometastases from Breast Cancer: Toxicity Data of a Prospective Non-Randomized Phase II Trial.
Franceschini D, Comito T, Di Gallo A, Vernier V, Marzo MA, Di Cristina L, Marini B, Lo Faro L, Stefanini S, Spoto R, Dominici L, Franzese C, Scorsetti M. Franceschini D, et al. Among authors: stefanini s. Curr Oncol. 2022 Oct 17;29(10):7858-7867. doi: 10.3390/curroncol29100621. Curr Oncol. 2022. PMID: 36290898 Free PMC article. Clinical Trial.
Predictive value of clinical and radiomic features for radiation therapy response in patients with lymph node-positive head and neck cancer.
Franzese C, Lillo S, Cozzi L, Teriaca MA, Badalamenti M, Di Cristina L, Vernier V, Stefanini S, Dei D, Pergolizzi S, De Virgilio A, Mercante G, Spriano G, Mancosu P, Tomatis S, Scorsetti M. Franzese C, et al. Among authors: stefanini s. Head Neck. 2023 May;45(5):1184-1193. doi: 10.1002/hed.27332. Epub 2023 Feb 23. Head Neck. 2023. PMID: 36815619
Internal Guidelines for Reducing Lymph Node Contour Variability in Total Marrow and Lymph Node Irradiation.
Dei D, Lambri N, Stefanini S, Vernier V, Brioso RC, Crespi L, Clerici E, Bellu L, De Philippis C, Loiacono D, Navarria P, Reggiori G, Bramanti S, Rodari M, Tomatis S, Chiti A, Carlo-Stella C, Scorsetti M, Mancosu P. Dei D, et al. Among authors: stefanini s. Cancers (Basel). 2023 Feb 28;15(5):1536. doi: 10.3390/cancers15051536. Cancers (Basel). 2023. PMID: 36900326 Free PMC article.
Radiation Therapy in the Management of Adrenal Metastases.
Franzese C, Stefanini S, Scorsetti M. Franzese C, et al. Among authors: stefanini s. Semin Radiat Oncol. 2023 Apr;33(2):193-202. doi: 10.1016/j.semradonc.2022.11.001. Semin Radiat Oncol. 2023. PMID: 36990636 Review.
Long term update on toxicity and survival of a phase II trial of linac-based stereotactic body radiation therapy for low-intermediate risk prostate cancer.
D'Agostino GR, Badalamenti M, Stefanini S, Baldaccini D, Franzese C, Faro LL, Di Cristina L, Vernier V, Reggiori G, Scorsetti M. D'Agostino GR, et al. Among authors: stefanini s. Prostate. 2024 Mar;84(4):368-375. doi: 10.1002/pros.24657. Epub 2023 Dec 19. Prostate. 2024. PMID: 38112222 Clinical Trial.
Predictive Factors for Long-Term Disease Control in Systemic Treatment-Naïve Oligorecurrent Renal Cell Carcinoma Treated with Up-Front Stereotactic Ablative Radiotherapy (SABR).
Franzese C, Vernier V, Badalamenti M, Lucchini R, Stefanini S, Bertolini A, Ilieva M, Di Cristina L, Marini B, Franceschini D, Comito T, Spoto R, Dominici L, Galdieri C, Mancosu P, Tomatis S, Scorsetti M. Franzese C, et al. Among authors: stefanini s. Cancers (Basel). 2024 Aug 25;16(17):2963. doi: 10.3390/cancers16172963. Cancers (Basel). 2024. PMID: 39272821 Free PMC article.
125 results